Hasnur Zaman Hashima, Shahrin Tarmizi Che Abdullaha, Wan Aliaa Wan Sulaimanb, Fan Kee Hoob, Hamidon Basrib
a Department of Internal Medicine, International Islamic University Malaysia, Kuantan, Pahang, Malaysia
b Neurology Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia
Abstract
Duchenne muscular dystrophy (DMD) is an incurable disease and the search for a cure is a challenging journey. However, with recent encouraging progress, we are seeing a light at the end of a long tunnel. This review focuses on several main strategies in gene therapy, including truncated dystrophin gene transfer via viral vectors, antisense mediated exon skipping to restore the reading frame, and read-through of translation stop codons. An exon skipping agent, eteplirsen, and a termination codon read drug, ataluren, are currently the most promising therapies. With better understanding of the molecular mechanism, gene therapy has improved with regard to the key areas of gene stability, safety, and route of delivery. Consequently, it has emerged as an exciting and hopeful means for novel treatment of this devastating disease.
Keywords
Cure; Duchenne; Gene therapy; Muscular dystrophy